SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Week 48 safety and efficacy of a rilpivirine (TMC278)‐based regimen in HIVinfected treatment‐naïve adolescents: PAINT Phase II trial - Patricia FlynnView Slideset
TSTavitiya SudjaritrukMD, ScM, PhDSlidesetHIVInternational Workshop on HIV & Pediatrics 2015Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease and Liver Fibrosis among Perinatally HIV‐infected Asian Adolescents - Tavitiya SudjaritrukView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Hepatitis B Treatment Response to TDF in 3TC‐experienced Perinatally HIVinfected Adolescents - Linda AurpibulView Slideset
RVRachel VreemanMD, MSSlidesetHIVInternational Workshop on HIV & Pediatrics 2015Innovative Adherence Interventions for HIV‐Infected Youth - Rachel Vreeman, MD, MSView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Anxiety and depression in young people with perinatal HIV and their HIV negative siblings - Marthe Le PrevostView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Bridging Worlds: Perinatally‐Infected Youth and Transition to Adult Care - Caroline Foster, MBBS, MRCPCHView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Efavirenz‐based therapy may simplify antiretroviral LPV‐based therapy initiated in HIV‐1‐infected children before the age of 2 in West‐Africa: the MONOD trial ANRS 12206 - Valeriane LeroyView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Reasons for delayed ART initiation in children with HIV in South Africa - Chloe TeasdaleView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Durability of first‐line antiretroviral therapy (ART) in children in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) - Ruth GoodallView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015The effect of systemic exposure to efavirenz, sex and age on the risk of virological non‐suppression in HIV‐infected African children - Andrzej BienczakView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Lopinavir ritonavir (1:1 ratio) in the presence of rifampicin is not inferior to lopinavir ritonavir (4:1 ratio) in the absence of rifampicin in HIV children. Interim analysis of an open label sequential non- randomized phar- Mark CottonView Slideset
SlidesetHIVInternational Workshop on HIV & Pediatrics 2015Virologic Outcomes of Children Switched from Lopinavir/Ritonavir‐ to Efavirenz‐Based Antiretroviral Treatment: a retrospective cohort study - Kirsten ReichmuthView Slideset
